Bibliography
- Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2006;69(11):1945-53
- Kidney Disease: improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD–MBD). Kidney Int 2009;76(Suppl 113):S1-S130
- Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 2014;10(5):268-78
- Locatelli F, Del Vecchio L, Violo L, Pontoriero G. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf 2014;13(5):551-61
- Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54(4):619-37
- Locatelli F, Del Vecchio L. Optimal phosphate control: still an unmet need in chronic kidney disease patients. Expert Opin Pharmacother 2014;15(3):307-9
- Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006;21(8):2217-24
- Frazão JM, Adragão T. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects. Nephron Clin Pract 2012;120(2):c108-19
- Wu-Wong JR, Mizobuchi M. Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease? Expert Opin Investig Drugs 2014;1-11, doi:10.1517/13543784.2014.933808
- Available from: http://clinicaltrials.gov/ct2/home
- Hatakeyama S, Murasawa H, Narita T, et al. Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis. BMC Nephrol 2013;14:222
- Ito K, Takeshima A, Shishido K, et al. Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms. Ther Apher Dial 2014;18(Suppl 2):19-23
- Gen S, Sasaki T, Saito K, et al. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride. Ther Apher Dial 2014;18(Suppl 2):8-12
- Savica V, Calò LA, Santoro D, et al. Salivary glands: a new player in phosphorus metabolism. J Ren Nutr 2011;21(1):39-42
- Block GA, Persky MS, Shamblin BM, et al. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease. Nephron Clin Pract 2013;123(1-2):93-101
- Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014;86(3):638-47
- Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005;90(3):1519-24
- Larsson T, Olauson H. [A brief update on FGF23 for the clinical nephrologist]. G Ital Nefrol 2014;31(2). pii: gin/31.2.11
- Crisafulli A, Romeo A, Floccari F, et al. Osteoprotegerin and bone mineral density in hemodiafiltration patients. Ren Fail 2005;27(5):531-9
- Cernaro V, Lacquaniti A, Lupica R, et al. Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein. Med Res Rev 2014;34(1):77-105
- Xu R. Semaphorin 3A: a new player in bone remodeling. Cell Adh Migr 2014;8(1):5-10
- Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23(8):1407-15
- Ureña-Torres P, Prié D, Keddad K, et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrol 2014;15:71
- Nagano N, Miyata S, Abe M, et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006;69(3):531-7
- Olauson H, Larsson TE. FGF23 and Klotho in chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22(4):397-404
- Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012;122(7):2543-53